Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.

@article{Tuscano2014LenalidomidePR,
  title={Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.},
  author={Joseph M Tuscano and Mrinal P Dutia and Karen Chee and Ann Brunson and Christine Reed-Pease and Mehrdad Abedi and Jeanna Welborn and Robert T O'donnell},
  journal={British journal of haematology},
  year={2014},
  volume={165 3},
  pages={375-81}
}
This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…